Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886089 | 0.93 | TAAR1 (0.50) | TAAR1P2RX3P2RX2HTR2ACETP | |
| SCHEMBL17862081 | 0.83 | TAAR1 (0.59) | TAAR1P2RX3P2RX2HTR2APOLB | |
| SCHEMBL9886097 | 0.81 | TAAR1 (0.59) | TAAR1HTR2A | |
| SCHEMBL5166833 | 0.81 | P2RX3 (0.45) | P2RX3P2RX2HTR2ACETPPOLB | |
| SCHEMBL13351579 | 0.79 | TAAR1 (0.55) | TAAR1P2RX3P2RX2HTR2ASTING1 | |
| SCHEMBL14404558 | 0.79 | DPP4 (0.38) | — | |
| SCHEMBL21142303 | 0.79 | GAA (0.48) | P2RX3P2RX2POLBGAAGFER | |
| SCHEMBL7720458 | 0.79 | TAAR1 (0.62) | TAAR1HTR2A | |
| SCHEMBL13085628 | 0.79 | P2RX3 (0.43) | P2RX3P2RX2HTR2AGAA | |
| SCHEMBL23731995 | 0.79 | TAAR1 (0.42) | TAAR1P2RX3P2RX2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175754-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | PML, TARDBP, PRNP | TAAR1 4083/4885P2RX3 3763/4885P2RX2 3901/4885 |
| US-20220175754-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | PML, TARDBP, PRNP | TAAR1 4083/4885P2RX3 3763/4885P2RX2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.